nach oben

Erschienen in:

26.03.2019 | Original Article

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

verfasst von: Christophe Massard, Jean-Charles Soria, Jürgen Krauss, Michael Gordon, Albert Craig Lockhart, Erik Rasmussen, Vijay V. Upreti, Sonal Patel, Gataree Ngarmchamnanrith, Haby Henary

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC).

Methods

This was an open-label, adaptive dose-exploration study in patients with relapsed/refractory ccRCC. The study was conducted in two parts for dose exploration and dose expansion on a biweekly dosing schedule. AMG 172 doses of 0.15, 0.3, 0.6, 1.2, 1.6, 1.8, and 2.4 mg/kg were studied in the dose-exploration phase.

Results

The 1.6 mg/kg dose of AMG 172 was identified as the maximum tolerated dose (MTD). The most common adverse events were thrombocytopenia (59%), nausea (54%), decreased appetite (49%), vomiting (46%), and fatigue (35%). The most common dose-limiting toxicity (DLT) was thrombocytopenia. Thrombocytopenia and liver injury constituted DLTs that required discontinuation of treatment. Of the 10 patients treated at the MTD in part 2 of the study, 2 patients had grade 3 hepatocellular injury with aspartate aminotransferase or alanine aminotransferase elevation. Pharmacokinetic profiles indicated low levels of circulating unconjugated antibody and unconjugated cytotoxin. Dose-proportional increases in plasma exposure were observed over the dose range of 0.3–2.4 mg/kg. Following multiple biweekly doses, plasma accumulation was less than two-fold. Two patients (5.4%) had a partial response, 6 patients (16.2%) had stable disease, and 13 patients (35.1%) had progressive disease.

Conclusion

AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate.

Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R (2017) Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(6):804–834. https://doi.org/10.6004/jnccn.2017.0100 CrossRefPubMed

Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, Heng DYC, Satkunasivam R, Finelli A (2018) First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol 74(3):309–321. https://doi.org/10.1016/j.eururo.2018.03.036 CrossRefPubMed

Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, Falk B, Cosman D, Baker E, Sutherland GR, Grabstein KH, Farrah T, Giri JG, Beckmann MP (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73(3):447–456. https://doi.org/10.1016/0092-8674(93)90133-B CrossRefPubMed

Bullock TN, Yagita H (2005) Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8⁺ T cell responses in the absence of CD4⁺ T cells. J Immunol 174(2):710–717. https://doi.org/10.4049/jimmunol.174.2.710 CrossRefPubMed

Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA (1994) CD70 represents the human ligand for CD27. Int Immunol 6(3):477–480. https://doi.org/10.1093/intimm/6.3.477 CrossRefPubMed

Held-Feindt J, Mentlein R (2002) CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 98(3):352–356. https://doi.org/10.1002/ijc.10207 CrossRefPubMed

Ranheim EA, Cantwell MJ, Kipps TJ (1995) Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85(12):3556–3565PubMed

Hishima T, Fukayama M, Hayashi Y, Fujii T, Ooba T, Funata N, Koike M (2000) CD70 expression in thymic carcinoma. Am J Surg Pathol 24(5):742–746CrossRef

Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173(6):2150–2153. https://doi.org/10.1097/01.ju.0000158121.49085.ba CrossRefPubMed

10.

Pich C, Sarrabayrouse G, Teiti I, Mariamé B, Rochaix P, Lamant L, Favre G, Maisongrosse V, Tilkin-Mariamé AF (2016) Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer 114(1):63–70. https://doi.org/10.1038/bjc.2015.412 CrossRefPubMed

11.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328–2337. https://doi.org/10.1158/0008-5472.CAN-05-2883 CrossRefPubMed

12.

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL (2012) CD70 expression patterns in renal cell carcinoma. Hum Pathol 43(9):1394–1399. https://doi.org/10.1016/j.humpath.2011.10.014 CrossRefPubMedPubMedCentral

13.

Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95(3):298–306. https://doi.org/10.1038/sj.bjc.6603222 CrossRefPubMedPubMedCentral

14.

Zhou Y, Whitehead J (2003) Practical implementation of Bayesian dose-escalation procedures. Drug Inf J 37(1):45–59. https://doi.org/10.1177/009286150303700108 CrossRef

15.

Whitehead J, Williamson D (1998) Bayesian decision procedures based on logistic regression models for dose-finding studies. J Biopharm Stat 8(3):445–467. https://doi.org/10.1080/10543409808835252 CrossRefPubMed

16.

Gabrielsson J, Weiner D (2012) Non-compartmental analysis. Methods Mol Biol 929:377–389. https://doi.org/10.1007/978-1-62703-050-2_16 CrossRefPubMed

17.

Chow V, Fanslow W, Hinkle B, Patel S, Upreti V, Retter M, Hill J, Paccaly A (2014) Translating preclinical toxicology, PK and PK/PD for tumor volume (xenografts) to support AMG 172 first in human study. Poster T2048. Presented at the AAPS National Biotechnology Conference, San Diego, CA

18.

Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, Ehrlicher A, Larson MK, Hoffmeister K, Hartwig JH, Italiano JE Jr (2010) Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 191(4):861–874. https://doi.org/10.1083/jcb.201006102 CrossRefPubMedPubMedCentral

19.

Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, Karki S, Morrison K, Yang P, Ou J, Moriya R, Shostak Y, Malik F, Nadell R, Liu W, Satpayev D, Atkinson J, Joseph IB, Pereira DS, Challita-Eid PM, Stover DR (2016) AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res 22(8):1989–1999. https://doi.org/10.1158/1078-0432.CCR-15-1542 CrossRefPubMed

20.

Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246–1257. https://doi.org/10.1007/s10637-014-0151-0 CrossRefPubMed

21.

Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD (2013) A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 24(7):1256–1263. https://doi.org/10.1021/bc400217g CrossRefPubMed

22.

Thomas LJ, Vitale L, O’Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T (2016) Development of a novel antibody-drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1. Mol Cancer Ther 15(12):2946–2954. https://doi.org/10.1158/1535-7163.MCT-16-0393 CrossRefPubMed

23.

Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ (2016) First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol 77(1):155–162. https://doi.org/10.1007/s00280-015-2909-2 CrossRefPubMed

Titel: First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
verfasst von: Christophe Massard
Jean-Charles Soria
Jürgen Krauss
Michael Gordon
Albert Craig Lockhart
Erik Rasmussen
Vijay V. Upreti
Sonal Patel
Gataree Ngarmchamnanrith
Haby Henary
Publikationsdatum: 26.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03796-4

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma